Exceptional level of biotechnology innovation in Europe means a tie for the Most Innovative EU Biotech SME 2012

21-Sep-2012 - In an exciting twist, two companies have been announced as winners of EuropaBio’s Most Innovative Biotech SME Award 2012. Commission Vice President Tajani who presented the award, during the event hosted by Dr. Kay Swinburne MEP at the European Parliament, named both Austrian healthcare biotech ...

ProtAffin AG starts Phase 1 study for lead product PA401 in inflammatory lung disease

28-Jun-2012 - ProtAffin AG announced that it has started dosing healthy volunteers in a Phase 1 clinical study in the UK with its novel investigational anti-inflammatory product, PA401.PA401 is a modified form of the human chemokine IL-8. Human IL-8 (CXCL8) is a chemokine produced by macrophages and other ...

ProtAffin AG announces preclinical data in Multiple Sclerosis for MCP-1 decoy program

24-Oct-2011 - ProtAffin AG announced preclinical data on its MCP-1 decoy program in a model of multiple sclerosis at the ECTRIMS/ACTRIMS conference.The Company presented a poster on its MCP-1 decoy program at the Immunomodulation session at the ECTRIMS/ACTRIMS conference, which is the 5th Joint Triennial ...

ProtAffin AG appoints Dr Mike Bartley as Chief Development Officer

28-Sep-2011 - ProtAffin AG announced that it has appointed Dr. Mike Bartley to the Management Board as Chief Development Officer. In this role, Dr. Bartley will lead the preclinical and clinical development activities at ProtAffin.Prior to joining ProtAffin, Dr. Bartley worked for 10 years at Pfizer Inc. in ...

ProtAffin AG strengthens Supervisory Board

28-Jul-2011 - ProtAffin AG announced that it has strengthened its Supervisory Board with the appointment of two new members. Dr Frank Walsh, CEO of Ossianix Inc. is joining the Supervisory Board as the new Chairman, and takes over the role from Kreske Nickelsen from Aescap Venture Management. At the same time, ...

ProtAffin AG granted patent in EU for CellJammer discovery technology

Novel technology enables development of a new class of biopharmaceuticals

15-Mar-2011 - ProtAffin AG announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals. The Company has initially applied this technology to chemokines, a large class of ...

ProtAffin AG announces preclinical data in COPD for lead product PA401

22-Sep-2010 - ProtAffin AG presents compelling preclinical data in chronic obstructive pulmonary disease (COPD) for its lead product PA401 at the European Respiratory Society Congress in Barcelona, Spain. The Company presents efficacy data for PA401, a glycan-binding decoy protein based on human chemokine ...

ProtAffin AG signs manufacturing contract for PA401 with CMC Biologics A/S

29-Jul-2010 - ProtAffin AG announced it has signed a manufacturing contract with CMC Biologics’ Danish operations, located in Copenhagen, Denmark for manufacture of its lead product PA401 for the treatment of chronic obstructive pulmonary disease (COPD). The contract will cover manufacture and supply of PA401 ...

ProtAffin AG Granted Patent in USA For Lead Anti-inflammatory Product PA401

14-Sep-2009 - ProtAffin AG announced that it has been granted a patent by the United States Patent and Trademark Office on anti-inflammatory variants of chemokine IL-8, including the Company’s lead product PA401. PA401 is an IL-8 variant in pre-clinical development at ProtAffin to treat chronic lung ...

ProtAffin AG Granted Patent in EU for Lead Anti-inflammatory Product PA401

28-Jan-2009 - ProtAffin AG announced that it has been granted a patent by the European Patent Office on anti-inflammatory variants of chemokine IL-8, including the Company’s lead product PA401. PA401 is an IL-8 variant in pre-clinical development at ProtAffin to prevent inflammation in a number of chronic and ...